Successful treatment of severe psoriasis relapse with Secukinumab(IL17 A inhibitor) after abrupt Brodalumab (IL17 receptor inhibitor) discontinuation: A retrospective study evaluating long term efficacy and safety

https://ift.tt/2G8vYba